OSLO, Norway, November 18, 2026
Photocure ASA has entered into a global supply and distribution agreement with Clinigen to expand access to Hexvix®/Cysview® (hexaminolevulinate hydrochloride) through a Named Patient Program (NPP) in more than 40 markets where the product is not approved or commercially available through Photocure or its distribution partners. The agreement is intended to help physicians access the bladder cancer diagnostic agent for individual patients when clinically appropriate and permitted under local regulations. The initiative strengthens Photocure’s commitment to uro-oncology precision diagnostics while leveraging Clinigen’s international pharmaceutical access and distribution capabilities. Through the program, eligible patients in markets where Hexvix/Cysview is unavailable may benefit from access to blue light cystoscopy (BLC), an imaging-assisted diagnostic procedure used in the detection and management of bladder cancer.
Named Patient Program Expands Access in 40+ Markets
The Named Patient Program (NPP) provides a regulatory pathway through which healthcare professionals can request medicines for individual patients when those products are not licensed, commercially available, or otherwise accessible in their country, subject to applicable local requirements. Under the agreement, physicians treating patients with suspected or recurrent bladder tumors will be able to request Hexvix/Cysview where the product is not locally approved or marketed and where the program is legally permitted. The initiative builds on Photocure’s initial Named Patient Program established in South Africa in 2024 and expands the arrangement to more than 40 additional markets. The program is designed to address access barriers for patients who may benefit from blue light cystoscopy but lack access to Hexvix through conventional commercial channels. Photocure emphasized that the program is intended to broaden access in countries where blue light cystoscopy equipment is already available, enabling physicians to use the diagnostic procedure when appropriate for individual patients.
Hexvix Supports Blue Light Cystoscopy for Bladder Cancer
Hexvix/Cysview contains hexaminolevulinate hydrochloride, which preferentially accumulates in bladder cancer cells and produces fluorescence that appears bright pink under blue light during cystoscopy. Blue light cystoscopy using Hexvix/Cysview is used as an adjunct to standard white light cystoscopy to help physicians detect and manage bladder cancer in patients with known or suspected disease, where approved. Compared with white light cystoscopy alone, the technique can improve tumor visualization, support more complete tumor resection, help identify residual tumors, and contribute to clinical management decisions. Bladder cancer remains a significant global healthcare burden, with approximately 635,000 new cases and more than 227,000 deaths reported worldwide in 2024. The disease is associated with a substantial recurrence risk, requiring many patients to undergo repeated cystoscopic surveillance and ongoing clinical management. Improved visualization of bladder tumors is therefore important in supporting diagnostic assessment, treatment planning, and disease monitoring, particularly in patients with recurrent or non-muscle-invasive bladder cancer.
Clinigen to Manage Global Supply and Distribution
Under the agreement, Photocure will supply Hexvix/Cysview to Clinigen, which will coordinate worldwide distribution through a central warehouse in the United Kingdom. The centralized distribution model is intended to improve supply-chain efficiency and support reliable delivery across participating markets. Clinigen will also provide support through dedicated local-language personnel to facilitate international access and coordination with healthcare professionals. The partnership combines Photocure’s expertise in bladder cancer diagnostics and product supply with Clinigen’s established global pharmaceutical access infrastructure, operating across more than 130 countries. Photocure stated that the initiative aligns with its sustainability and patient-access objectives by making Hexvix available to patients who otherwise may not have access to the blue light cystoscopy procedure. The collaboration represents an expansion of the companies’ efforts to address pharmaceutical access barriers and strengthen the availability of specialized diagnostic medicines internationally. By establishing a structured Named Patient Program across more than 40 markets, the agreement aims to support physicians, improve access to diagnostic options, and extend the reach of fluorescence-guided bladder cancer detection in regions where the technology and appropriate clinical infrastructure are already in place.
Source: Photocure press release


